Uterine Leiomyoma (Uterine Fibroids) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Uterine leiomyoma (uterine fibroids) pipeline market research report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects.
Key Targets in the Uterine Fibroids Pipeline Market
The key targets in the uterine fibroids pipeline market report are Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, and Collagen. Gonadotropin Releasing Hormone Receptor has the highest number of pipeline products in the uterine fibroids pipeline market.
Uterine Fibroids Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Uterine Fibroids Pipeline Market
The key MoA in the uterine fibroids pipeline market report are Gonadotropin Releasing Hormone Receptor Antagonist, Gonadotropin Releasing Hormone Receptor Agonist, Progesterone Receptor Agonist, Collagen Inhibitor, and Progesterone Receptor Antagonist. Gonadotropin Releasing Hormone Receptor Antagonist has the highest number of pipeline products.
Uterine Fibroids Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Uterine Fibroids Pipeline Market
The key RoA in the uterine fibroids pipeline market report are oral, parenteral, subcutaneous, and intramuscular. Oral has the highest number of pipeline products.
Uterine Fibroids Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Uterine Fibroids Pipeline Market
The key molecule type in the uterine fibroids pipeline market report are small molecule, synthetic peptide, enzyme, vaccine. Small molecule has the highest number of pipeline products.
Uterine Fibroids Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Uterine Fibroids Pipeline Market
The key companies in the uterine fibroids pipeline market report are Kissei Pharmaceutical Co Ltd, Richter Gedeon Nyrt, AbbVie Inc, Bayer AG, Context Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Endo International Plc, and Eurofarma Laboratorios SA. Kissei Pharmaceutical Co Ltd has the highest number of pipeline products.
Uterine Fibroids Pipeline Market, by Companies
To know about more companies, download a free report sample
Market report overview
Key targets | Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, and Collagen |
Key MoA | Gonadotropin Releasing Hormone Receptor Antagonist, Gonadotropin Releasing Hormone Receptor Agonist, Progesterone Receptor Agonist, Collagen Inhibitor, and Progesterone Receptor Antagonist |
Key RoA | Oral, Parenteral, Subcutaneous, and Intramuscular |
Key molecule type | Small Molecule, Synthetic Peptide, Enzyme, Vaccine |
Key companies | Kissei Pharmaceutical Co Ltd, Richter Gedeon Nyrt, AbbVie Inc, Bayer AG, Context Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Endo International Plc, and Eurofarma Laboratorios SA |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Non Malignant Disorders).
- The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uterine Leiomyoma (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uterine Leiomyoma (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Non Malignant Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Non Malignant Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Bayer AG
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Endo International Plc
Eurofarma Laboratorios SA
Evestra Inc
GeneScience Pharmaceuticals Co Ltd
Immunitor Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Richter Gedeon Nyrt
TiumBio Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the uterine fibroids pipeline market?
The key targets in the uterine fibroids pipeline market report are Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, and Collagen.
-
What are the key MoA in the uterine fibroids pipeline market?
The key MoA in the uterine fibroids pipeline market report are Gonadotropin Releasing Hormone Receptor Antagonist, Gonadotropin Releasing Hormone Receptor Agonist, Progesterone Receptor Agonist, Collagen Inhibitor, and Progesterone Receptor Antagonist.
-
What are the key RoA in the uterine fibroids pipeline market?
The key RoA in the uterine fibroids pipeline market report are oral, parenteral, subcutaneous, and intramuscular.
-
What are the key molecule types in the uterine fibroids pipeline market?
The key molecule type in the uterine fibroids pipeline market report are small molecule, synthetic peptide, enzyme, vaccine.
-
What are the key companies in the uterine fibroids pipeline market?
The key companies in the uterine fibroids pipeline market report are Kissei Pharmaceutical Co Ltd, Richter Gedeon Nyrt, AbbVie Inc, Bayer AG, Context Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Endo International Plc, and Eurofarma Laboratorios SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.